The efficacy of PCSK9 inhibitors on major cardiovascular events and lipid profile in patients with diabetes: a systematic review and meta-analysis of randomized controlled trials.
Egidio ImbalzanoFederica IlardiLuana OrlandoBasilio PintaudiGianluigi SavareseGiuseppe M C RosanoPublished in: European heart journal. Cardiovascular pharmacotherapy (2023)
PCSK9i appear to be effective in reducing the risk of MACE and in improving lipid profiles of subjects with diabetes and dyslipidemia.